



Clearside Biomedical, Inc. to Report Third Quarter 2016 Financial Results and Host Conference Call on Wednesday, November 9, 2016

November 2, 2016

ALPHARETTA, Ga., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, announced today that its third quarter 2016 financial results will be released at 7:00 a.m. on Wednesday, November 9, 2016. Following the release, Clearside will host a live conference call and webcast at 8:30 a.m. EST to discuss the Company's financial results and provide a general business and strategic review.

The live webcast and a replay may be accessed by visiting the "Investor Relations" section at www.clearsidebio.com. Please connect to Clearside's website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be required to access the webcast. Alternately, please call (844) 263-8310 (U.S.) or (213) 358-0959 (international) to listen to the live conference call. The conference ID number for the live call is 12007881. Please dial in approximately 10 minutes prior to the call. An archive of the webcast will be available until November 30, 2016.

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a publicly-traded, late-stage clinical biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye using Clearside's proprietary microinjector to access diseased tissue through the suprachoroidal space. Clearside holds intellectual property protecting the delivery of drugs of any type through the suprachoroidal space. Clearside has a portfolio of clinical and preclinical programs using drug administration through the suprachoroidal space to provide a route of access to treat diseases of the back-of-the-eye such as retinal vein occlusion (RVO), uveitis, neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Clearside is currently enrolling patients in a Phase 3 clinical trial (PEACHTREE) for the treatment of patients with macular edema associated with non-infectious uveitis and has initiated IND-enabling preclinical studies for the treatment of wet AMD. Visit www.clearsidebio.com for more information.

Contacts

Company:

Charles Deignan
Chief Financial Officer
678-270-4005
charlie.deignan@clearsidebio.com

Investors:

Matthew BeckThe Trout Group
646-378-2933
mbeck@troutgroup.com



Clearside Biomedical, Inc.